JP6253991B2 - 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 - Google Patents

肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 Download PDF

Info

Publication number
JP6253991B2
JP6253991B2 JP2013556750A JP2013556750A JP6253991B2 JP 6253991 B2 JP6253991 B2 JP 6253991B2 JP 2013556750 A JP2013556750 A JP 2013556750A JP 2013556750 A JP2013556750 A JP 2013556750A JP 6253991 B2 JP6253991 B2 JP 6253991B2
Authority
JP
Japan
Prior art keywords
liver
hepatitis
ileal brake
composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013556750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506928A5 (enExample
JP2014506928A (ja
Inventor
ジェローム シェンターク，
ジェローム シェンターク，
ジョセフ， エム． フェイヤッド，
ジョセフ， エム． フェイヤッド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46758432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6253991(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/932,633 external-priority patent/US9757346B2/en
Application filed by Individual filed Critical Individual
Publication of JP2014506928A publication Critical patent/JP2014506928A/ja
Publication of JP2014506928A5 publication Critical patent/JP2014506928A5/ja
Application granted granted Critical
Publication of JP6253991B2 publication Critical patent/JP6253991B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998—Hordeum (barley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2013556750A 2011-03-02 2012-02-24 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 Expired - Fee Related JP6253991B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12/932,633 US9757346B2 (en) 2008-09-03 2011-03-02 Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes)
US12/932,633 2011-03-02
US201161480788P 2011-04-29 2011-04-29
US61/480,788 2011-04-29
US201161514174P 2011-08-02 2011-08-02
US61/514,174 2011-08-02
US201161551638P 2011-10-26 2011-10-26
US61/551,638 2011-10-26
PCT/US2012/026561 WO2012118712A2 (en) 2011-03-02 2012-02-24 Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017228965A Division JP2018065840A (ja) 2011-03-02 2017-11-29 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法

Publications (3)

Publication Number Publication Date
JP2014506928A JP2014506928A (ja) 2014-03-20
JP2014506928A5 JP2014506928A5 (enExample) 2015-04-02
JP6253991B2 true JP6253991B2 (ja) 2017-12-27

Family

ID=46758432

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013556750A Expired - Fee Related JP6253991B2 (ja) 2011-03-02 2012-02-24 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
JP2017228965A Pending JP2018065840A (ja) 2011-03-02 2017-11-29 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
JP2019033502A Pending JP2019123716A (ja) 2011-03-02 2019-02-27 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017228965A Pending JP2018065840A (ja) 2011-03-02 2017-11-29 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
JP2019033502A Pending JP2019123716A (ja) 2011-03-02 2019-02-27 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法

Country Status (10)

Country Link
US (3) US9370528B2 (enExample)
EP (1) EP2680859B1 (enExample)
JP (3) JP6253991B2 (enExample)
KR (4) KR102198749B1 (enExample)
CN (2) CN110152000A (enExample)
AU (3) AU2012223528A1 (enExample)
BR (1) BR112013022391A2 (enExample)
EA (1) EA201391262A1 (enExample)
IL (2) IL228259B (enExample)
WO (1) WO2012118712A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155772B2 (en) 2008-12-08 2015-10-13 Philip Morris Usa Inc. Soft, chewable and orally dissolvable and/or disintegrable products
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
US9486463B2 (en) 2010-10-19 2016-11-08 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CN110152000A (zh) 2011-03-02 2019-08-23 J·深塔格 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
CN104903339A (zh) 2012-11-16 2015-09-09 卡迪夫大学学院顾问有限公司 用于制备核苷前体药物的方法
AU2014205553A1 (en) * 2013-01-08 2015-07-09 Volant Holdings Gmbh Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
BR112015022936A2 (pt) 2013-03-14 2017-07-18 J Schentag Jerome vesículas de colestossoma para a incorporação de moléculas em quilomícrons
CA2903493C (en) * 2013-03-15 2022-05-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
CA2939581C (en) * 2014-02-20 2024-01-23 Vaxart, Inc. Formulations for small intestinal delivery
WO2016011335A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
ES2832504T3 (es) 2015-06-12 2021-06-10 Vaxart Inc Formulaciones para administración de antígenos de norovirus y rsv en el intestino delgado
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
US10653678B2 (en) 2016-04-11 2020-05-19 Genfit Methods of treatment for cholestatic and fibrotic diseases
US11400078B2 (en) * 2016-04-11 2022-08-02 Genfit Methods of treatment for cholestatic and fibrotic diseases
SG11201808402RA (en) 2016-04-11 2018-10-30 Genfit Methods of treatment for cholestatic and fibrotic diseases
WO2017203367A2 (en) * 2016-05-22 2017-11-30 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
WO2018090049A1 (en) * 2016-11-14 2018-05-17 The Brigham And Women's Hospital, Inc. Estrogen sensing through gper1 regulates normal and malignant liver growth
MY203981A (en) 2017-01-27 2024-07-27 Genfit Pharmaceutical compositions for combination therapy
CA3054103A1 (en) 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
GB2571749A (en) * 2018-03-07 2019-09-11 Anabio Tech Limited A method inducing satiety in a mammal
WO2020120519A1 (en) 2018-12-10 2020-06-18 Aphaia Pharma Ag Combinatorial oral treatment of metabolic disorders through orchestrated release of enterokines
PL3666262T3 (pl) 2018-12-10 2022-02-28 Aphaia Ip Ag Farmaceutyczne doustne postaci dawkowania do leczenia zaburzeń metabolicznych i powiązanych chorób poprzez zorganizowane uwalnianie enterokin
CN109568284B (zh) * 2018-12-29 2020-04-24 广东中润药物研发有限公司 一种替诺福韦艾拉酚胺肠溶片及其制备方法
CN110478357A (zh) * 2019-07-23 2019-11-22 哈尔滨医科大学 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
AR121356A1 (es) 2020-02-18 2022-05-11 Gilead Sciences Inc Compuestos antivirales
CN116096352A (zh) 2020-06-10 2023-05-09 阿帕亚知识产权公司 含有与胶凝剂组合的多个剂型的肠因子释放物质的药物组合物
ES3028915T3 (en) 2021-04-16 2025-06-20 Gilead Sciences Inc Methods of preparing carbanucleosides using amides
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
JP7109827B1 (ja) * 2021-11-16 2022-08-01 株式会社ハニック・ホワイトラボ 抗ウイルス剤
EP4595967A1 (en) * 2022-09-01 2025-08-06 HLB Genex, Inc. Bacillus species strain expressing superoxide dismutase, bacillus species strain spore and/or superoxide dismutase, and use thereof for preventing or treating of fibrotic disease
WO2025119939A1 (en) 2023-12-03 2025-06-12 Aphaia Pharma Ag Treatment of obesity and related conditions by circadian administration of enterokine-stimulating compositions
LU103233B1 (en) 2023-12-21 2025-06-24 Aphaia Ip Ag Treatment of obesity and related conditions by circadian administration of enterokine-stimulating compositions

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51133489A (en) * 1975-05-14 1976-11-19 Tokyo Daigaku Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities
US4544550A (en) 1982-10-05 1985-10-01 Rodolfo Almanzor Y Method for the treatment of diabetes
US5194464A (en) 1988-09-27 1993-03-16 Takeda Chemical Industries, Ltd. Enteric film and preparatoin thereof
US5769793A (en) 1989-09-08 1998-06-23 Steven M. Pincus System to determine a relative amount of patternness
US5120563A (en) * 1989-12-21 1992-06-09 The Procter & Gamble Company Food compositions containing reduced calorie fats and reduced calorie sugars
DE69332045T2 (de) * 1992-02-04 2002-10-17 Chiron Corp., Emeryville Hepatistherapeutikum
US5322697A (en) 1992-05-28 1994-06-21 Meyer James H Composition and method for inducing satiety
US5976548A (en) 1994-11-08 1999-11-02 Viva America Marketing, Inc. Nutritional supplement composition and use
CN1194831A (zh) * 1997-04-01 1998-10-07 李春华 利巴韦林大输液系列制剂
BR9910505A (pt) * 1998-05-15 2001-01-02 Schering Corp Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60045082D1 (de) 2000-06-07 2010-11-18 Watson Pharmaceuticals Inc Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin
WO2004000280A1 (en) 2002-04-29 2003-12-31 Shire Laboraties, Inc. Pharmaceutical formulations with improved bioavailability
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
EP1462116A1 (en) 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
WO2005110455A2 (en) 2004-05-13 2005-11-24 Intermune, Inc. Combination therapy for treating hepatitis virus infection
WO2006034463A2 (en) 2004-09-23 2006-03-30 Herbalife International, Inc. Herbal supplement to support weight loss
CA2577821A1 (en) 2004-09-24 2006-04-06 Merck & Co., Inc. Combination therapy for the treatment of obesity
US20060093592A1 (en) 2004-10-04 2006-05-04 Nutracea Synbiotics
CA2608709A1 (en) * 2005-05-31 2006-12-07 Novartis Ag Treatment of liver diseases in which iron plays a role in pathogenesis
JP2007001945A (ja) 2005-06-24 2007-01-11 Tsuneo Ozeki 癌治療剤
WO2007022518A2 (en) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
CN101291685A (zh) * 2005-08-19 2008-10-22 安米林药品公司 治疗糖尿病和降低体重的毒蜥外泌肽
CA2621577C (en) 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US8394845B2 (en) 2006-10-30 2013-03-12 Hanall Biopharma Co., Ltd. Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
CN101646419A (zh) * 2006-11-08 2010-02-10 诺瓦瓦克斯股份有限公司 制备多相药物组合物的固体剂型的方法
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US20070172525A1 (en) 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
JP2011519915A (ja) 2008-05-05 2011-07-14 オラムド エルティーディー． エクセナチドの経口投与用の方法および組成物
US9757346B2 (en) 2008-09-03 2017-09-12 Volant Holdings Gmbh Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes)
WO2010027498A2 (en) * 2008-09-03 2010-03-11 New Science Holdings, Llc Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
CN102316872B (zh) 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
US20100297075A1 (en) 2009-02-12 2010-11-25 Arqule, Inc. Combinational compositions and methods for treatment of cancer
CN102438599B (zh) 2009-03-04 2015-01-21 迈雅营养品有限公司 通过降低血糖水平来控制糖尿病的营养组合物和方法
RU2410108C1 (ru) 2009-08-03 2011-01-27 Государственное образовательное учреждение высшего профессионального образования "Орловский государственный технический университет" (ОрелГТУ) Способ скармливания пробиотика поросятам-сосунам
US8999721B2 (en) 2009-10-23 2015-04-07 Therabrake, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US8367418B2 (en) 2009-10-23 2013-02-05 Therasyn Sensors, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US20140294951A1 (en) 2011-10-26 2014-10-02 Joseph M. Fayad Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
CN110152000A (zh) 2011-03-02 2019-08-23 J·深塔格 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
AU2014205553A1 (en) 2013-01-08 2015-07-09 Volant Holdings Gmbh Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Also Published As

Publication number Publication date
US20130337055A1 (en) 2013-12-19
WO2012118712A2 (en) 2012-09-07
AU2012223528A8 (en) 2017-05-11
EP2680859B1 (en) 2022-04-27
AU2017202713A1 (en) 2017-05-18
US20160279157A1 (en) 2016-09-29
WO2012118712A3 (en) 2013-04-04
CN103635196A (zh) 2014-03-12
AU2012223528A1 (en) 2013-10-24
US9730951B2 (en) 2017-08-15
KR20200006177A (ko) 2020-01-17
CN110152000A (zh) 2019-08-23
US9370528B2 (en) 2016-06-21
EP2680859A2 (en) 2014-01-08
IL258450A (en) 2018-05-31
AU2019201917A1 (en) 2019-04-11
KR20140147657A (ko) 2014-12-30
EA201391262A1 (ru) 2014-03-31
KR20190060879A (ko) 2019-06-03
BR112013022391A2 (pt) 2018-01-16
KR102198749B1 (ko) 2021-01-06
CN103635196B (zh) 2019-05-07
JP2019123716A (ja) 2019-07-25
IL228259B (en) 2019-05-30
JP2014506928A (ja) 2014-03-20
JP2018065840A (ja) 2018-04-26
KR20180118236A (ko) 2018-10-30
EP2680859A4 (en) 2014-12-17
US20180125870A1 (en) 2018-05-10
US10245277B2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
JP6253991B2 (ja) 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法
US10624913B2 (en) Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
JP2014533733A (ja) Ｃ型肝炎ウイルスを処置するための組成物および方法
JP2018532720A (ja) 線維症の治療のためのセニクリビロック併用療法
JP2017528431A (ja) 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム
EP2771023A1 (en) Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d
JP2014506928A5 (enExample)
WO2017203367A2 (en) Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
JP2017528499A (ja) 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
US12337024B2 (en) Larazotide formulations
CN107028954A (zh) 门鸟氨酸在制备防治脂肪肝药物中的用途
HK40010279A (en) Compositions for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
US20170319540A1 (en) Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis
HK1192143B (zh) 用於单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物、治疗方法和诊断方法
HK1192143A (en) Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
OA17352A (en) Compositions and methods for treating hepatitis C virus.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171129

R150 Certificate of patent or registration of utility model

Ref document number: 6253991

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees